These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
14. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988 [TBL] [Abstract][Full Text] [Related]
15. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. Oldgren J; Johnston N; Siegbahn A Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482 [TBL] [Abstract][Full Text] [Related]
16. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma. Rezaie AR Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805 [TBL] [Abstract][Full Text] [Related]
17. Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation. Stief TW Clin Appl Thromb Hemost; 2006 Apr; 12(2):137-61. PubMed ID: 16708116 [TBL] [Abstract][Full Text] [Related]